These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

563 related items for PubMed ID: 29151104

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
    Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H.
    Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group.
    Iriyama N, Ohashi K, Hashino S, Kimura S, Nakaseko C, Takano H, Hino M, Uchiyama M, Morita S, Sakamoto J, Sakamaki H, Inokuchi K.
    Intern Med; 2018 Jan 01; 57(1):17-23. PubMed ID: 29033428
    [Abstract] [Full Text] [Related]

  • 7. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.
    Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H.
    Am J Hematol; 2015 Sep 01; 90(9):819-24. PubMed ID: 26103598
    [Abstract] [Full Text] [Related]

  • 8. Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving Time of BCR::ABL1 IS Transcript Levels.
    Ceran F, Akıncı S, Uçar MA, Korkmaz G, Gündüz M, Çavdarlı B, Bakanay ŞM, Falay M, Dağdaş S, Dilek İ, Özet G.
    Turk J Haematol; 2022 Aug 25; 39(3):196-203. PubMed ID: 35620443
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report.
    Massimino M, Stella S, Tirrò E, Consoli ML, Pennisi MS, Puma A, Vitale SR, Romano C, Zammit V, Stagno F, DI Raimondo F, Manzella L.
    Anticancer Res; 2019 Jul 25; 39(7):3949-3954. PubMed ID: 31262926
    [Abstract] [Full Text] [Related]

  • 12. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL.
    Clin Ther; 2012 Feb 25; 34(2):272-81. PubMed ID: 22285209
    [Abstract] [Full Text] [Related]

  • 13. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
    Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, Mohamed H, Healey D, Kantarjian H, Hochhaus A, Saglio G.
    Am J Hematol; 2016 Sep 25; 91(9):869-74. PubMed ID: 27192969
    [Abstract] [Full Text] [Related]

  • 14. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
    Schiffer CA, Cortes JE, Hochhaus A, Saglio G, le Coutre P, Porkka K, Mustjoki S, Mohamed H, Shah NP.
    Cancer; 2016 May 01; 122(9):1398-407. PubMed ID: 26998677
    [Abstract] [Full Text] [Related]

  • 15. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
    Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM.
    Cancer; 2020 Jan 01; 126(1):67-75. PubMed ID: 31553487
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.
    Kim DD, Lee H, Kamel-Reid S, Lipton JH.
    Br J Haematol; 2013 Mar 01; 160(5):630-9. PubMed ID: 23278256
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of Generic Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Multicenter Prospective Study in China.
    Yu W, Du X, Wang W, Lou J, Liu P, Meng L, Jin J.
    Clin Lymphoma Myeloma Leuk; 2022 Sep 01; 22(9):e867-e873. PubMed ID: 35842355
    [Abstract] [Full Text] [Related]

  • 19. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
    Hochhaus A, Müller MC, Radich J, Branford S, Kantarjian HM, Hanfstein B, Rousselot P, Kim DW, Lipton JH, Bleickardt E, Lambert A, Hughes TP.
    Leukemia; 2009 Sep 01; 23(9):1628-33. PubMed ID: 19641527
    [Abstract] [Full Text] [Related]

  • 20. Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.
    Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM.
    Cancer; 2018 Jul 01; 124(13):2740-2747. PubMed ID: 29723397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.